FY2029 Earnings Forecast for ATOS Issued By HC Wainwright

Atossa Therapeutics, Inc. (NASDAQ:ATOS - Free Report) - Investment analysts at HC Wainwright issued their FY2029 earnings per share (EPS) estimates for shares of Atossa Therapeutics in a research note issued on Thursday, January 30th. HC Wainwright analyst E. Bodnar forecasts that the company will earn ($0.14) per share for the year. HC Wainwright has a "Buy" rating and a $7.00 price objective on the stock. The consensus estimate for Atossa Therapeutics' current full-year earnings is ($0.22) per share.

A number of other research analysts have also recently weighed in on ATOS. StockNews.com cut shares of Atossa Therapeutics from a "hold" rating to a "sell" rating in a research note on Monday, November 18th. Ascendiant Capital Markets upped their price objective on Atossa Therapeutics from $6.50 to $7.00 and gave the company a "buy" rating in a research note on Monday, December 9th.

Atossa Therapeutics Trading Down 4.9 %

Shares of NASDAQ:ATOS traded down $0.04 during midday trading on Monday, reaching $0.77. The company had a trading volume of 779,824 shares, compared to its average volume of 789,018. The stock has a market cap of $96.29 million, a P/E ratio of -3.48 and a beta of 1.24. The company's 50 day moving average price is $0.99 and its 200 day moving average price is $1.25. Atossa Therapeutics has a 52-week low of $0.72 and a 52-week high of $2.31.

Hedge Funds Weigh In On Atossa Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ATOS. SG Americas Securities LLC lifted its stake in shares of Atossa Therapeutics by 254.3% during the 3rd quarter. SG Americas Securities LLC now owns 41,849 shares of the company's stock valued at $64,000 after buying an additional 30,037 shares in the last quarter. Intech Investment Management LLC bought a new stake in Atossa Therapeutics during the 3rd quarter valued at $29,000. The Manufacturers Life Insurance Company purchased a new stake in shares of Atossa Therapeutics during the third quarter worth $75,000. State Street Corp boosted its holdings in shares of Atossa Therapeutics by 4.2% in the third quarter. State Street Corp now owns 1,732,221 shares of the company's stock worth $2,633,000 after acquiring an additional 69,180 shares during the period. Finally, XTX Topco Ltd grew its position in shares of Atossa Therapeutics by 101.2% in the third quarter. XTX Topco Ltd now owns 49,616 shares of the company's stock valued at $75,000 after purchasing an additional 24,951 shares in the last quarter. Institutional investors own 12.74% of the company's stock.

About Atossa Therapeutics

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.